摘要
背景:纳米技术涉及原子和分子尺度上的材料制造。根据国家纳米技术倡议,纳米技术是指这些结构CH在至少一维范围内接近于1−100 nm的尺寸范围。 目的:纳米药物给药技术已被证实为在体内和体外都具有不同性质的纳米载体,可用于靶向药物治疗各种疾病,特别是针对各种疾病。特别是肿瘤。在过去几年里,人们对利用纳米技术开发各种新的药物输送系统的问题十分关注。不同的纳米器件或纳米载体,如脂质体MES、树状大分子、聚合物、转移体和纳米粒等已被用于靶向药物的传递。 结论:综述了纳米载体的制备方法及其在肿瘤中的潜在应用。
关键词: 纳米技术,纳米载体,靶向,挖掘输送,肿瘤。
图形摘要
Current Drug Targets
Title:Nanocarrier Based Advances in Drug Delivery to Tumor: An Overview
Volume: 19 Issue: 13
关键词: 纳米技术,纳米载体,靶向,挖掘输送,肿瘤。
摘要: Background: Nanotechnology deals with the manufacturing of materials at the atomic and molecular scale. According to the National Nanotechnology Initiative, nanotechnology denotes those structures which are nearly in 1−100 nm size regime in at least one dimension.
Objective: Nanotechnology in drug delivery has been evidenced into nanocarriers that possess distinct properties both in vitro and in vivo, which may be used in targeting drugs to various diseases especially tumors. In the last few years, there has been a keen concern in the formulation of various new drug delivery systems employing nanotechnology. Different nanodevices or nanocarriers like liposomes, dendrimers, polymersomes, transfersomes, and nanoparticles etc. have been employed for the targeted drug delivery.
Conclusion: This review summarizes the advances in nanocarriers in terms of their methods of preparation and potential applications especially in tumors.
Export Options
About this article
Cite this article as:
Nanocarrier Based Advances in Drug Delivery to Tumor: An Overview, Current Drug Targets 2018; 19 (13) . https://dx.doi.org/10.2174/1389450119666180131105822
DOI https://dx.doi.org/10.2174/1389450119666180131105822 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers